February 2024
13 Dec 2024
The global shingles vaccine market revenue was valued at USD 4.94 billion in 2024 and is expected to attain around USD 17.83 billion by 2033, growing at a CAGR of 15.34% during the forecast period. The demand for the shingles vaccine market is increasing due to the growing risk of shingles in the elderly population.
Shingle is an infectious disease that causes a rash on the back. Generally, this rash is found on the left and right sides of the torso. It is caused by the virus named varicella-zoster virus, which is also responsible for the occurrence of chickenpox. The virus stays in the body for a longer period and after many years it gets reactivated which leads to shingles. Shingles are a common disease across the world, mainly in developing and highly dense populations including India and China. Commonly found in individuals aged 50 or more.
Increasing cases of herpes zoster
the rising cases of herpes zoster across the world are expected to raise vaccine uptake in a few years. The high risk associated with herpes zoster is expected to drive the adoption of shingles vaccines. Especially the aging population with impaired immunity is prone to this disease creates significant opportunities in the market. In addition, the development of more efficient and higher-duration vaccines can impact the shingles vaccine market growth positively.
Government Initiatives
Many countries are identifying the role of preventive healthcare and are deploying policies to raise vaccine coverage among the older population. Also, government campaigns supporting favorable reimbursement policies to develop advanced vaccines can create lucrative opportunities for the shingles vaccine market. Moreover, strong healthcare infrastructure development, particularly in developing nations like India and China.
Rising healthcare expense
The market can experience significant growth due to increasing healthcare expenditure, particularly for preventative healthcare measures can lead to the shingles vaccine market expansion. Furthermore, the rise in the burden of the aging population across the globe can promote heavy investments in the vaccine production process. These advancements are observed in vaccine manufacturing and distribution.
North America dominated the shingles vaccine market in 2023. The dominance of the region can be credited to the rise in favorable reimbursement policies, substantial uptake of vaccines, and the presence of major industry players in the region. Also, the region's high recommendation for vaccination can impact market growth exponentially over the forecast period. In North American, the U.S. led the market due to the high prevalence of shingles and the inclusion of shingles vaccines in the Regional Immunization Program.
Asia Pacific is projected to grow at the fastest rate in the shingles vaccine market over the studied period. The growth of the region can be credited to the growing disposable incomes, enhancements in healthcare policy, and the high amount of population who are at high risk of shingles. Furthermore, the ongoing endorsement of Shingrix across numerous Asian nations further propels market growth in the region. In Asia Pacific, Japan experienced remarkable growth because of the rapidly escalating elderly population in the country who are more susceptible to shingles disease.
| Report Attribute | Key Statistics |
| Market Revenue in 2024 | USD 4.94 Billion |
| Market Revenue by 2033 | USD 17.83 Billion |
| CAGR | 15.34% from 2024 to 2033 |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2023 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
By Product
By Vaccine Type
Get this report to explore global market size, share, CAGR and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/5340
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344
February 2024
October 2023
July 2023
July 2022